Get the Daily Brief
Latest Biotech News
Alpha Tau Medical’s alpha radiation therapy induces systemic anti-cancer immune response
Alpha Tau Medical’s Alpha DaRT Phase 3 trials demonstrate 100% tumor response in treating solid tumors by delivering localized alpha radiation directly into lesions. Notably, the treatment elicits...
European biotech investment hurdle: Integration and market focus needed for growth
Industry leaders at BIO 2025 highlighted Europe's rich scientific innovation contrast with challenges in business integration, clinical trials, and fundraising compared to the U.S. Fragmented hubs...
Viome Partners With Scripps on At-Home RNA Test for Colon Cancer Screening
Viome Life Sciences and Scripps Research have launched a collaboration to develop an at-home RNA screening test aimed at early detection of precancerous colon polyps. The initiative involves a...
Takeda’s Orexin Agonist Shows Positive Phase 3 Results in Narcolepsy
Takeda’s orexin receptor 2-selective agonist, oveporexton (formerly TAK-861), achieved all primary and secondary endpoints across two Phase 3 trials targeting narcolepsy. The oral drug...
FDA Rejects Ultragenyx’s Gene Therapy Over Manufacturing Issues
Ultragenyx Pharmaceuticals received a complete response letter from the U.S. Food and Drug Administration concerning its AAV-based gene therapy UX111 for Sanfilippo syndrome due to manufacturing...
Evercore Initiates Guardant Health Coverage With Bullish Outlook
Investment bank Evercore ISI initiated coverage of Guardant Health, assigning an Outperform rating with a $60 price target. Evercore projects over 20% annual top-line growth through 2027, driven...
WHO Adds Gilead’s Twice-Yearly HIV PrEP Injection to Guidelines
Following FDA approval, the World Health Organization expanded its global HIV prevention guidelines to include Gilead Sciences’ twice-yearly cabotegravir injection for pre-exposure prophylaxis....
Integrated Biosciences Unveils Optogenetic Drug Screening Platform
Integrated Biosciences introduced a novel optogenetic screening platform enabling precise modulation of biological pathways with light. Applying this technology, the company screened over 370,000...
AstraZeneca’s Blood Pressure Drug Baxdrostat Achieves Phase 3 Success
AstraZeneca announced positive Phase 3 results for baxdrostat, an aldosterone synthase inhibitor for treatment-resistant hypertension. The drug met primary and secondary endpoints in a late-stage...
Alpha Tau Medical’s Alpha DaRT Shows Promising Cancer Immunotherapy Results
Alpha Tau Medical reported encouraging Phase 3 clinical trial results for Alpha DaRT, a localized alpha radiation therapy for solid tumors. The treatment elicits both local tumor control and...
Genetic Diversity Influences Tumor Response to Immunotherapy
A study using genetically diverse Collaborative Cross mouse models revealed that inherited genetic variability significantly affects tumor response to immune checkpoint inhibitors. Published in...
Multi-Protein Misfolding Identified as Contributor to Alzheimer’s Beyond Amyloids
Johns Hopkins researchers used limited proteolysis mass spectrometry to identify over 200 misfolded proteins associated with cognitive decline in aging rat brains, suggesting that neurological...
Takeda’s narcolepsy drug posts twin phase 3 victories, FDA filing imminent
Takeda Pharmaceutical is advancing its orexin receptor 2 (OX2R)-selective agonist toward regulatory submission after achieving two positive phase 3 trial outcomes. These results position the drug...
AstraZeneca’s $1.3B CinCor acquisition validated by hypertension phase 3 success
AstraZeneca's sizable $1.3 billion investment in CinCor Pharmaceuticals gains justification with a positive phase 3 trial of baxdrostat, an aldosterone synthase inhibitor. Conducted in 796...
Repligen and Univercells unite on real-time viral vector biomanufacturing monitoring
Repligen Technologies and Univercells Technologies announced a collaboration integrating Repligen’s MAVEN® Real Time Glucose Control Platform into Univercells' scale-X bioreactors to deliver...
Genetic diversity influences tumor response to immunotherapy, mouse model reveals
Research using the Collaborative Cross mouse model, designed for genetic variability, elucidates how inherited genetic differences impact tumor response to immune checkpoint inhibitors. Findings,...
Novel ubiquitination pathway modulated by cypin shapes synaptic plasticity for brain therapeutics
A Rutgers University study uncovers the role of the protein cypin in regulating synaptic content through K63-linked polyubiquitination (polyUb), a post-translational modification previously...
Emerging Alzheimer’s research reveals hundreds of misfolded proteins beyond amyloids
Johns Hopkins researchers employing limited proteolysis mass spectrometry (LiP-MS) identified over 200 misfolded proteins associated with cognitive decline in aged rat models, challenging the...
Study links wildfire smoke exposure to heightened cardiovascular events and mortality
A large-scale study analyzing 3.2 million adults in Northern California found a significant increase in cardiovascular hospitalizations and mortality during the 2018 Mendocino Complex wildfire...
Marathon running induces reversible decreases in brain myelin content, study finds
Magnetic resonance imaging of 10 marathon runners revealed significant short-term reductions in myelin water fraction, a proxy for myelin, in key white matter regions immediately post-race. These...